EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics
The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessin…
Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board
Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). At GlaxoSmit…
CANDEL THERAPEUTICS APPOINTS PHARMA VETERAN AND IMMUNOLOGIST PAUL-PETER TAK, M.D., PH.D., AS CHIEF EXECUTIVE OFFICER; EXPANDS LEADERSHIP TEAM WITH CHIEF FINANCIAL OFFICER, CHIEF BUSINESS OFFICER AND CHIEF REGULATORY OFFICER APPOINTMENTS
– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response– Phase 3 prostate cancer program enrolling patients, clinica…
Pioneering Gut Science, Kintai Therapeutics Is Bringing a New Small Molecule Modality to Fruition
What if the gut, widely regarded as the body’s second brain, could offer a much more impactful means to effect broad systemic pharmacological actions of orally administered drugs based on the conflu…
Ten Pillars of Success for Building a Biotech Company (or any Innovative Organization)
First year reflections: Ten Pillars of Success for Building a Biotech Company
View Article: https://www.linkedin.com/pulse/ten-pillars-success-building-biotech-company-any-innovative-tak/
Biocentury
Tak lands at Candel, with plans to speed up development of immunotherapy’s play late-stage assets
GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. C…
Candel Aims High In Next Stage Of Cancer Immunotherapy Mission
Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.
View Article:…
GlaxoSmithKline Scientist Steps Down to Join Flagship Pioneering
Dr Tak’s new role will help oversee scientific ventures to find transformative treatments for conditions such as cancer, neurodegenerative disease and autoimmune diseases.
https://www.businessle…
Going with Your Gut Instinct
I’ve been interested in this field since before the term “microbiome” was coined. In the 1990s, I conducted research at Leiden University Medical Center on the role of microorganisms in the pathogen…
